- Home
- DSY vs ALGS Comparison
DSY vs ALGS Comparison
Compare DSY & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSY
- ALGS
- Stock Information
- Founded
- DSY 2020
- ALGS 2018
- Country
- DSY China
- ALGS United States
- Employees
- DSY N/A
- ALGS N/A
- Industry
- DSY
- ALGS Biotechnology: Pharmaceutical Preparations
- Sector
- DSY
- ALGS Health Care
- Exchange
- DSY Nasdaq
- ALGS Nasdaq
- Market Cap
- DSY 110.7M
- ALGS 118.8M
- IPO Year
- DSY N/A
- ALGS 2020
- Fundamental
- Price
- DSY $2.17
- ALGS $18.63
- Analyst Decision
- DSY
- ALGS Strong Buy
- Analyst Count
- DSY 0
- ALGS 1
- Target Price
- DSY N/A
- ALGS $75.00
- AVG Volume (30 Days)
- DSY 106.0K
- ALGS 263.3K
- Earning Date
- DSY 02-10-2025
- ALGS 03-11-2025
- Dividend Yield
- DSY N/A
- ALGS N/A
- EPS Growth
- DSY 120.37
- ALGS N/A
- EPS
- DSY 0.01
- ALGS N/A
- Revenue
- DSY $7,323,356.00
- ALGS $5,997,000.00
- Revenue This Year
- DSY N/A
- ALGS N/A
- Revenue Next Year
- DSY N/A
- ALGS N/A
- P/E Ratio
- DSY $166.38
- ALGS N/A
- Revenue Growth
- DSY 16.37
- ALGS N/A
- 52 Week Low
- DSY $0.75
- ALGS $6.76
- 52 Week High
- DSY $13.47
- ALGS $46.80
- Technical
- Relative Strength Index (RSI)
- DSY 48.11
- ALGS 33.33
- Support Level
- DSY $1.79
- ALGS $20.12
- Resistance Level
- DSY $2.20
- ALGS $24.33
- Average True Range (ATR)
- DSY 0.38
- ALGS 2.67
- MACD
- DSY 0.08
- ALGS -0.38
- Stochastic Oscillator
- DSY 67.33
- ALGS 4.38
About DSY Big Tree Cloud Holdings Limited Ordinary Shares
Big Tree Cloud Holdings Ltd is a consumer-oriented, mission-driven, and technology-empowered company engaged in the development, production, and sales of personal care products and other consumer goods. In particular, it is focused on the development and production of feminine pads and other feminine hygiene products. Through its platform, the company focuses on high-quality product development, deep customer engagement, and efficient sales and marketing.
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.